Biomea Fusion Inc

NASDAQ BMEA

Download Data

Biomea Fusion Inc Total Liabilities to Total Assets Ratio 1 year YoY Change (%) for the year ending December 31, 2023: -4.42%

Biomea Fusion Inc Total Liabilities to Total Assets Ratio 1 year YoY Change (%) is -4.42% for the year ending December 31, 2023, a -101.34% change year over year. The total liabilities to total assets ratio measures the proportion of total liabilities to total assets. It is calculated by dividing the total liabilities by the total assets. This ratio provides insights into the company's financial leverage and the proportion of its assets financed by liabilities. A higher ratio indicates a higher level of financial risk and reliance on liabilities for asset acquisition. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Biomea Fusion Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2022 was 0.16, a 330.89% change year over year.
  • Biomea Fusion Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2021 was 0.04, a -95.94% change year over year.
  • Biomea Fusion Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2020 was 0.92, a -15.00% change year over year.
  • Biomea Fusion Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2019 was 1.08.
NASDAQ: BMEA

Biomea Fusion Inc

CEO Mr. Thomas Andrew Butler
IPO Date April 16, 2021
Location United States
Headquarters 900 Middlefield Road, Redwood City, CA, United States, 94063
Employees 110
Sector Healthcare
Industry Biotechnology
Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Similar companies

EWTX

Edgewise Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email